共 50 条
- [41] Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer? [J]. CANCER MEDICINE, 2016, 5 (09): : 2314 - 2322
- [42] Quality of Life Outcomes for Low- and Intermediate-Risk Prostate Cancer Patients Treated With 5-Fraction Stereotactic Body Radiation Therapy [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E249 - E249
- [43] Comparison of Active Surveillance, Low-Dose-Rate Brachytherapy, Stereotactic Ablative Body Radiation Therapy, and Standard External Beam in Low-Risk Prostate Cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S447 - S447
- [44] Comparison of the Biochemical Recurrence Risk between Radical Prostatectomy and Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (08): : 655 - 660
- [47] Biochemical Control and Toxicity Outcomes of SBRT vs LDR Brachytherapy in the Treatment of Low and Intermediate Risk Prostate Cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E862 - E862
- [48] Decreased PSA Nadir as a Result of Dose-Escalated Stereotactic Body Radiation for Patients With Low- and Intermediate-Risk Prostate Cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E28 - E29
- [49] Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma [J]. RADIATION ONCOLOGY JOURNAL, 2016, 34 (04): : 260 - 264
- [50] Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (04): : 745 - 751